Wright Medical Technology
This article was originally published in The Gray Sheet
Executive SummaryLaunches the S.O.S. (segmented oncology system) proximal femur implant. The S.O.S., which was cleared via 510(k) in June, is composed of "titanium modular pieces and is designed around a self-locking taper." The implant will provide surgeons with "maximum operative flexibility" in situations including "oncology, severe bone loss of the proximal femur, revision and trauma cases," Wright claims. The company estimates the cost of the S.O.S. is "approximately one-half the cost associated with similar custom-manufactured implants"
You may also be interested in...
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.
The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019.